Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1443551
This article is part of the Research Topic Hepatocellular Carcinoma: From Diagnostic Approaches to Surgical and Systemic Therapies View all 7 articles

A systematic review and meta-analysis comparing the impact of tenofovir and entecavir on the prognosis of hepatitis B virusrelated hepatocellular carcinoma patients undergoing liver resection

Provisionally accepted
  • Zhejiang Taizhou Hospital, Taizhou, China

The final, formatted version of the article will be published soon.

    Background: Tenofovir (TDF) and entecavir (ETV) are highly effective and welltolerated nucleos(t)ide analogs commonly prescribed for hepatitis virus B (HBV)treatment. Yet, it's unclear if survival outcomes differ for HBV-related hepatocellular carcinoma (HCC) patients treated with ETV or TDF. Thus, this meta-analysis aimed to compare the prognostic effectiveness of ETV and TDF in HBV-related HCC patients.Methods: We comprehensively searched four databases -PubMed, Web of Science, Embase, and the Cochrane Library -to identify pertinent studies utilizing keywords "entecavir," "tenoforvir," "hepatocellular carcinoma," and "liver resection." Our primary outcomes of interest encompassed overall survival (OS), recurrence-free survival (RFS), early recurrence, and late recurrence. The statistical effect size for these measures was expressed in terms of hazard ratios (HR).Results: Our search resulted in 10 studies encompassing 11 datasets involving 7400 patients. Our meta-analysis revealed that patients treated with TDF achieved better OS (HR=0.53; 95% confidence interval (CI) =0.40-0.70, p < 0.0001), RFS (HR=0.68; 95% CI= 0.57-0.80; p < 0.0001), early recurrence (HR=0.80; 95% CI= 0.67-0.94; p < 0.0077), and late recurrence (HR=0.64; 95% CI=0.43-0.97; p = 0.0368). We detected publication bias, potentially affecting OS but not RFS. Conclusion: Our findings demonstrated that TDF outperformed ETV regarding RFS for HBV-related HCC patients. However, to bolster the evidence and establish more conclusive conclusions, further validation via extensive and high-quality randomized controlled trials is essential.

    Keywords: hepatocellular carcinoma (HCC), entecavir, tenofovir, liver resection, 40 meta-analysis, prognosis 41 42

    Received: 04 Jun 2024; Accepted: 08 Jul 2024.

    Copyright: © 2024 Hu, Yang, Qiao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Aidong Wang, Zhejiang Taizhou Hospital, Taizhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.